ClinicalTrials.gg
TerminatedNCT01925612Updated Jun 21, 2018Results posted

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2 interventional study of brentuximab vedotin and brentuximab vedotin in Lymphoma, B-cell and Lymphoma, Large B-cell, Diffuse, sponsored by Seagen Inc.. Terminated at 51 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-21.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization and changing treatment landscape in frontline DLBCL

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse — 4 open to participants now, 8 under way, 1 of them phase 3. Vincristine · Lymphoma, Large B-Cell, Diffuse.

Enrollment
13th of 41
87 · median 50
Started
2013
with 1 other
Phase 2
24 of 43
2 open now
Registered
26th of 43
by date
Lead sponsor
2 of 43
Seagen Inc.

Among the 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse, this one is the 13th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2013, is one of 24 in phase 2, and was the 26th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

4 of the 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About vincristine

Vincristine: first FDA approval 1963 (ONCOVIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This study has 3 parts. The purpose of Part 1 of this study is to assess the safety and efficacy of brentuximab vedotin in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (known as BV+RCHOP) in patients with DLBCL who have never been treated. Patients will be randomly assigned in a 1:1 ratio to receive RCHOP together with 1 of 2 doses of brentuximab vedotin. Patients will be tested to see if there is a difference in side effects between the 2 groups.

The purpose of Part 2 of this study is to assess the safety and efficacy of brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) (known as BV+RCHP) in patients with CD30-positive DLBCL who have never been treated. Patients will be enrolled to receive RCHP together with 1.8mg/kg of brentuximab vedotin.

The purpose of Part 3 of this study is to assess the safety and efficacy of BV+RCHP compared to standard RCHOP in patients with CD30-positive DLBCL that have never been treated. Patients will be randomly assigned in a 1:1 ratio to receive either BV+RCHP or RCHOP. Patients will be tested to see if there is a difference in side effects between the 2 groups.

Read the detailed description

In the first part of this study, patients in the 2 groups were tested to see if there was a difference in the response to treatment and whether there were differences in the side effects (unwanted effects).

The second and third parts of the study are being done to see if there are any side effects (unwanted effects) of the higher dose of brentuximab vedotin when combined with a modified version of RCHOP that omits vincristine. The third part of the study is being done to see if there is a difference between BV+RCHP and RCHOP in the response to treatment.

03

Conditions studied

  • Lymphoma, B-cell
  • Lymphoma, Large B-cell, Diffuse

Browse trials for

Keywords

  • Antibodies, Monoclonal
  • Antibody-Drug Conjugate
  • Antigens, CD30
  • Drug Therapy
  • Hematologic Diseases
  • Lymphoma, B-cell
  • Lymphoma, Large B-cell, Diffuse
  • Monomethyl auristatin E
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 87 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naive patients with systemic de novo or transformed diffuse large B cell lymphoma (DLBCL) or follicular non-Hodgkin lymphoma (NHL) grade 3b
  • International Prognostic Index (IPI) score greater than or equal to 3 for patients greater than 60 years of age or age-adjusted IPI (aaIPI) score of 2 or 3 for patients less than or equal to 60 years of age
  • Stage IAX (bulk defined as single lymph node mass >10 cm in diameter), IB-IV disease
  • of at least 1.5 cm
  • (ECOG) performance status less than or equal to 2
  • Patients in Parts 2 and 3 must have confirmed diagnosis of CD30-positive DLBCL

Exclusion criteria

Exclusion Criteria:

  • Previous history of treated indolent lymphoma
  • History of another primary that has not been in remission for 3 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Part 1: BV(1.2 mg/kg) + RCHOP

    Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP.

    Drug: brentuximab vedotin · Drug: rituximab · Drug: vincristine · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin

  • Experimental
    Part 1: BV(1.8 mg/kg) + RCHOP

    Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP.

    Drug: brentuximab vedotin · Drug: rituximab · Drug: vincristine · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin

  • Experimental
    Part 2: BV(1.8 mg/kg) + RCHP

    Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP.

    Drug: brentuximab vedotin · Drug: rituximab · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin

  • Active comparator
    Part 3: RCHOP

    Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone.

    Drug: rituximab · Drug: vincristine · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin

  • Experimental
    Part 3: BV(1.8 mg/kg) + RCHP

    Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy. Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP.

    Drug: brentuximab vedotin · Drug: rituximab · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin

Interventions

  • 1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles

    Also known as: Adcetris, SGN-35

  • 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles

    Also known as: Adcetris, SGN-35

  • 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

  • 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)

  • 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

  • 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

  • 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

07

What researchers measure

Primary outcomes

  1. Complete Remission Rate

    Number (count) of participants that achieved remission according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).

    Time frame: Up to 6 months

  2. Incidence of Adverse Events

    Number (count) of participants that experienced at least 1 adverse event.

    Time frame: Up to 6 months

  3. Incidence of Laboratory Abnormalities

    Number (count) of participants that experienced a Grade 3 or higher maximum post-baseline laboratory toxicity (hematology and chemistry). Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), v4.03. Grade 1 = mild, no intervention needed; Grade 2 = moderate, minimal intervention needed; Grade 3 = severe or medically significant, hospitalization is required; Grade 4 = life-threatening, urgent intervention needed; Grade 5 = death related to adverse event.

    Time frame: Up to 6 months

Secondary outcomes

  1. Objective Response Rate

    Number (count) of participants that achieved complete or partial remission at the end of treatment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007)

    Time frame: Up to 6 months

  2. Progression-free Survival

    Median progression-free survival (in months) and observed minimum-maximum range.

    Time frame: Up to approximately 4 years

  3. Overall Survival

    Median overall survival (in months) and observed minimum-maximum range.

    Time frame: Up to approximately 4 years

08

Results

Posted Jun 21, 2018

Participant flow

Participant flow — Overall Study
MilestonePart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Started2922111112
Completed2518101010
Not completed44112
Withdrew: Progressive disease11100
Withdrew: Adverse event33012

Outcome measures

PrimaryComplete Remission Rate

Number (count) of participants that achieved remission according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Complete Remission Rate
ParticipantsPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Complete Remission Rate2016968
PrimaryIncidence of Adverse Events

Number (count) of participants that experienced at least 1 adverse event.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Incidence of Adverse Events2922111112
PrimaryIncidence of Laboratory Abnormalities

Number (count) of participants that experienced a Grade 3 or higher maximum post-baseline laboratory toxicity (hematology and chemistry). Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), v4.03. Grade 1 = mild, no intervention needed; Grade 2 = moderate, minimal intervention needed; Grade 3 = severe or medically significant, hospitalization is required; Grade 4 = life-threatening, urgent intervention needed; Grade 5 = death related to adverse event.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Incidence of Laboratory Abnormalities
ParticipantsPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Any Hematology Test1016464
Lymphocytes (x10^3/uL)815344
Absolute Neutrophil Count (x10^3/uL)44120
Neutrophils (x10^3/uL)44120
Leukocytes (x10^3/uL)32111
Hemoglobin (x10^3/uL)01010
Platelets (x10^3/uL)11000
Any Chemistry Test47213
Glucose (mg/dL)35001
Potassium (mEq)/L02112
Calcium (mg/dL)11000
Sodium (mEq/L)02000
Alanine Aminotransferase (IU/L)00100
SecondaryObjective Response Rate

Number (count) of participants that achieved complete or partial remission at the end of treatment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007)

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Objective Response Rate231910109
SecondaryProgression-free Survival

Median progression-free survival (in months) and observed minimum-maximum range.

Time frame:
Up to approximately 4 years
Reported as:
Median · Months
Progression-free Survival
MonthsPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Progression-free SurvivalNA (0.62 to 40.21)NA (1.28 to 39.85)NA (3.35 to 24.34)NA (3.25 to 15.41)NA (1.25 to 16.43)
SecondaryOverall Survival

Median overall survival (in months) and observed minimum-maximum range.

Time frame:
Up to approximately 4 years
Reported as:
Median · Months
Overall Survival
MonthsPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Overall SurvivalNA (0.62 to 42.79)NA (1.28 to 44.29)NA (16.56 to 25.76)NA (3.25 to 16.85)NA (1.25 to 19.22)

Adverse events

Collected over Adverse events were reported from study Day 1 (predose) though the EOT visit or 30 days after the last study treatment (Brentuximab vedotin or combination treatment), whichever was later. However, all protocol-related AEs were collected from the time of informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: BV(1.2 mg/kg) + RCHOP1/29 (3.4%)16/29 (55.2%)29/29 (100%)
Part 1: BV(1.8 mg/kg) + RCHOP2/22 (9.1%)14/22 (63.6%)22/22 (100%)
Part 2: BV(1.8 mg/kg) + RCHP0/11 (0%)5/11 (45.5%)11/11 (100%)
Part 3: BV(1.8 mg/kg) + RCHP1/11 (9.1%)4/11 (36.4%)11/11 (100%)
Part 3: RCHOP2/12 (16.7%)4/12 (33.3%)12/12 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
Febrile NeutropeniaBlood and lymphatic system disorders8/298/222/110/111/12
DiarrhoeaGastrointestinal disorders0/290/220/112/110/12
PancytopeniaBlood and lymphatic system disorders1/290/220/111/110/12
BacteraemiaInfections and infestations2/290/221/110/110/12
Pneumocystis jirovecii pneumoniaInfections and infestations0/290/221/110/110/12
PneumoniaInfections and infestations1/292/220/110/110/12
Escherichia sepsisInfections and infestations0/290/220/111/110/12
NauseaGastrointestinal disorders0/290/221/111/110/12
VomitingGastrointestinal disorders0/290/221/111/110/12
Gastric ulcer haemorrhageGastrointestinal disorders0/290/220/111/110/12
Most frequent other events
Showing 10 of 118
Most frequent other events
EventPart 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOP
NauseaGastrointestinal disorders14/2915/228/114/112/12
AlopeciaSkin and subcutaneous tissue disorders5/299/228/113/113/12
FatigueGeneral disorders17/2916/227/112/113/12
DiarrhoeaGastrointestinal disorders14/2915/223/116/111/12
Peripheral sensory neuropathyNervous system disorders16/2915/226/114/114/12
VomitingGastrointestinal disorders7/2914/222/112/110/12
ConstipationGastrointestinal disorders8/299/226/111/115/12
Decreased appetiteMetabolism and nutrition disorders7/2910/222/112/113/12
DyspnoeaRespiratory, thoracic and mediastinal disorders7/299/220/113/114/12
DehydrationMetabolism and nutrition disorders3/299/222/112/111/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
<=18 years000000
Between 18 and 65 years101175639
>=65 years191146646
Age, Continuous
Age, Continuous(years)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
Median70 (33 to 80)64 (21 to 81)59 (22 to 78)68 (46 to 74)65 (41 to 80)66 (21 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
Female136410639
Male161671646
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
Hispanic or Latino421018
Not Hispanic or Latino25188111173
Unknown or Not Reported022004
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
American Indian or Alaska Native000000
Asian011002
Native Hawaiian or Other Pacific Islander000000
Black or African American111104
White27178101274
More than one race000000
Unknown or Not Reported131005
Region of Enrollment
Region of Enrollment(participants)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
United States29221181082
Czechia000112
Poland000202
Italy000011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Part 1: BV(1.2 mg/kg) + RCHOPPart 1: BV(1.8 mg/kg) + RCHOPPart 2: BV(1.8 mg/kg) + RCHPPart 3: BV(1.8 mg/kg) + RCHPPart 3: RCHOPTotal
05414418
1161244339
28663528
09

Study locations

51 sites
  • Arizona Oncology Associates, PC - HAL
    Phoenix, Arizona 85016, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85710, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • City of Hope National Medical Center
    Duarte, California 91010-3000, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Cardinal Bernardin Cancer Center / Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Illinois Cancer Specialists / Advocate Lutheran General Hospital
    Niles, Illinois 60714, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Johns Hopkins Medical Center
    Baltimore, Maryland 21231, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Billings Clinic Cancer Research
    Billings, Montana 59101, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Summit Medical Group
    Morristown, New Jersey 07962, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07754, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Mid Ohio Oncology/Hematology Inc
    Columbus, Ohio 43219, United States
  • Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477, United States
  • Northwest Cancer Specialists, P.C.
    Tualatin, Oregon 97062, United States
  • Saint Francis Hospital / Bon Secours
    Greenville, South Carolina 29601, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37909, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705, United States
  • Texas Oncology - Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • US Oncology Investigational Products Center (IPC)
    Fort Worth, Texas 76177, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4095, United States
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78229, United States
  • US Oncology Central Regulatory
    The Woodlands, Texas 77380, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
  • Benaroya Research Institute/Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie
    Hradec Kralove, 500 05, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Centro di Riferimento Oncologico di Aviano
    Aviano, 33081, Italy
  • Instituto di Ematologia ed Oncologia Medica
    Bologna, 40138, Italy
  • Azienda Ospedaliero-Universitaria Pisana - Ospedale S. Chiara
    Pisa, 56126, Italy
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii
    Gdansk, 80-219, Poland
  • Malopolskie Centrum Medyczne S.C.
    Krakow, 30-510, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim
    Olsztyn, 10-228, Poland
  • Hospital de la Santa Creu i Sant Paul
    Barcelona, 08025, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Institut Català D'oncologia
    L'Hospitalet de Llobregat, 08907, Spain
  • Complejo Hospitalano de Navarra Servicio Hematologia
    Pamplona, 31130, Spain
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2013
First posted
Aug 20, 2013
Start
Aug 2013
Primary completionActual
May 1, 2017
CompletionActual
May 1, 2017
Results first posted
Jun 21, 2018
Last update
Jun 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01925612
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Aug 20, 2013
Start date
Aug 2013
Primary completion
May 1, 2017
Completion
May 1, 2017
Results posted
Jun 21, 2018
Last update
Jun 21, 2018

Study contacts

Katherine Ruffner
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Vincristine

Start the discussion